Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 458

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

Open access
Hellström‐Lindberg, Eva, Gulbrandsen, Nina, Lindberg, Greger, Ahlgren, Tomas, Dahl, Inger Marie S., Dybedal, Ingunn, Grimfors, Gunnar, Hesse‐Sundin, Eva, Hjorth, Martin, Kanter‐Lewensohn, Lena, Linder, Olle, Luthman, Michaela, Löfvenberg, Eva, Öberg, Gunnar, Porwit‐MacDonald, Anja, Rådlund, Anders, Samuelsson, Jan, Tangen, Jon Magnus, Winquist, Ingemar, Wisloff, Finn, for the Scandinavian MDS Group·2003·British Journal of Haematology

Abstract

Summary. We have published previously a prototype of a decision model for anaemic patients with myelodysplastic syndromes (MDS), in which transfusion need and serum erythropoietin (S‐Epo) were used to define three groups with different probabilities of erythroid response to treatment with granulocyte colony‐stimulating factor (G‐CSF) + Epo. S‐Epo ≤ 500 U/l and a transfusion need of < 2 units/month predicted a high probability of response to treatment, S‐Epo > 500 U/l and ≥ 2 units/month for a poor response, whereas the presence of only one negative prognostic marker predicted an intermediate response. A total of 53 patients from a prospective study were included in our evaluation sample. Patients with good or intermediate probability of response were treated with G‐CSF + Epo. The overall response rate was 42% with 28·3% achieving a complete and 13·2% a partial response to treatment. The response rates were 61% and 14% in the good and intermediate predictive groups respectively. The model retained a significant predictive value in the evaluation sample (P < 0·001). Median duration of response was 23 months. Scores for global health and quality of life (QOL) were significantly lower in MDS patients than in a reference population, and fatigue and dyspnoea was significantly more prominent. Global QOL improved in patients responding to treatment (P = 0·01). The validated decision model defined a subgroup of patients with a response rate of 61% (95% confidence interval 48–74%) to treatment with G‐CSF + Epo. The majority of these patients have shown complete and durable responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2003.04153.x

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 458

Metadata

Authors
Hellström‐Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I. M. S., Dybedal, I., Grimfors, G., Hesse‐Sundin, E., Hjorth, M., Kanter‐Lewensohn, L., Linder, O., Luthman, M., Löfvenberg, E., Öberg, G., Porwit‐MacDonald, A., Rådlund, A., Samuelsson, J., Tangen, J. M., Winquist, I., Wisloff, F., & for the Scandinavian MDS Group
Venue
British Journal of Haematology
Publisher
Wiley
Published
2003-03
Volume
120
Issue
6
Pages
1037-1046
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1996887331
Cited by
458
References
26
FWCI
10.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life. https://app.cochat.ai/papers/10.1046/j.1365-2141.2003.04153.x
The paper
Hellström‐Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I. M. S., Dybedal, I., Grimfors, G., Hesse‐Sundin, E., Hjorth, M., Kanter‐Lewensohn, L., Linder, O., Luthman, M., Löfvenberg, E., Öberg, G., Porwit‐MacDonald, A., Rådlund, A., Samuelsson, J., Tangen, J. M., Winquist, I., . . . for the Scandinavian MDS Group. (2003). A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2003.04153.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.